Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01723774 · ClinicalTrials.gov registry record · Phase 2
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
A Phase 2 study of Breast Neoplasms, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 4
- Study locations
NCT01723774: Active Phase 2 study of Breast Neoplasms, sponsored by Washington University School of Medicine.
NCT01723774 is a Phase 2 study of Breast Neoplasms that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 84 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01723774, a Phase 2 study of Breast Neoplasms, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic complete response rate when compared to the historical control of single agent aromatase inhibitors, 2) result in fewer patients with on therapy Ki67\>10% compared to historical control.
Primary Outcome
Complete cell cycle arrest is defined as Ki67 ≤ 2.7% following 2 weeks of neoadjuvant PD 0332991
Conditions Studied
Interventions
- DRUG Anastrozole
- DRUG Goserelin
- PROCEDURE Tumor biopsy
- DRUG PD0332991
- PROCEDURE Surgery (standard of care)
Study Locations (4)
Alabama
- University of Alabama - Birmingham
Arizona
- Mayo Clinic - Scottsdale - Scottsdale
Minnesota
- Mayo Clinic - Rochester - Rochester
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2013-04-10 |
| Est. Completion | 2026-08-24 |
| Phase | Phase 2 |
What the registry record for NCT01723774 still lists
NCT01723774 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Anastrozole is the first listed.
NCT01723774 reports a single indexed study location in Alabama, Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01723774 about?
NCT01723774 is a clinical study titled "PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer". A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic complete response rate wh...
What is the current status of trial NCT01723774?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2013-04-10. Estimated completion is 2026-08-24.
What conditions does trial NCT01723774 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT01723774?
The interventions under investigation include: Anastrozole (DRUG), Goserelin (DRUG), Tumor biopsy (PROCEDURE), PD0332991 (DRUG), Surgery (standard of care) (PROCEDURE).
Who is sponsoring clinical trial NCT01723774?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01723774 being conducted?
This trial has 4 study locations across Alabama, Arizona, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01723774's enrollment target sits among peer trials
84 61st of 97 higher than 37 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
-
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI